We are live on ! Find out more
ARLZ

Aralez Pharmaceuticals Inc.
ARLZ

Delisted

ARLZ was delisted on the 20th of August, 2018.

Back to rankings

72 hedge funds and large institutions have $21.5M invested in Aralez Pharmaceuticals Inc. in 2017 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 17 increasing their positions, 25 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% less funds holding

Funds holding: 78 → 72 (-6)

31% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 16

32% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 25

45% less call options, than puts

Call options by funds: $88K | Put options by funds: $159K

57% less capital invested

Capital invested by funds: $50.2M → $21.5M (-$28.7M)

Holders
72
Holders Change
-6
Holders Change %
-7.69%
% of All Funds
1.79%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
17
Reduced
25
Closed
16
Calls
$88K
Puts
$159K
Net Calls
-$71K
Net Calls Change
-$345K

Top Buyers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
+$367K
2
Deutsche Bank
Deutsche Bank
Germany
+$328K
3
IECM
Intrinsic Edge Capital Management
Illinois
+$289K
4
UBS Group
UBS Group
Switzerland
+$170K
5
BlackRock
BlackRock
New York
+$109K

Top Sellers

Rank Fund Capital Flow
1
ECP
Elk Creek Partners
Colorado
-$5.33M
2
BC
Broadfin Capital
New York
-$4.56M
3
JAM
JW Asset Management
Florida
-$1.61M
4
AC
Armistice Capital
New York
-$1.5M
5
PP
Prospector Partners
Connecticut
-$483K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
51
Citigroup
New York
$5K -$1.99K -1,376 -28%
Royal Bank of Canada
52
Royal Bank of Canada
Ontario, Canada
$4K -$402 -278 -9%
PCM
53
Prelude Capital Management
New York
$3K -$38.9K -26,900 -93%
WA
54
WFG Advisors
Texas
$3K +$3.61K +2,500 New
IA
55
IFP Advisors
Florida
$2K -$1.44K -1,000 -41%
Barclays
56
Barclays
United Kingdom
$1K -$46K -31,829 -99%
TRCT
57
Tower Research Capital (TRC)
New York
$1K -$31.2K -21,576 -99%
Bank of Montreal
58
Bank of Montreal
Ontario, Canada
$1K -$2.88K -1,994 -76%
JC
59
JBF Capital
Colorado
$1K – – –
JP Morgan Chase
60
JP Morgan Chase
New York
$1K – – –
SFG
61
SevenBridge Financial Group
Pennsylvania
$1K – – –
DOA
62
D'Orazio & Associates
Virginia
$1K +$416 +288 +40%
ECP
63
Elk Creek Partners
Colorado
– -$5.33M -2,488,475 Closed
AC
64
Armistice Capital
New York
– -$1.5M -700,000 Closed
PP
65
Prospector Partners
Connecticut
– -$483K -225,800 Closed
GPC
66
Glacier Peak Capital
Washington
– -$332K -155,200 Closed
PI
67
Putnam Investments
Massachusetts
– -$263K -122,766 Closed
Citadel Advisors
68
Citadel Advisors
Florida
– -$121K -83,537 Closed
FMA
69
FNY Managed Accounts
New York
– -$165K -77,119 Closed
BAS
70
Brown Advisory Securities
Maryland
– -$141K -66,000 Closed
PPA
71
Parametric Portfolio Associates
Washington
– -$81K -37,907 Closed
IAM
72
Integre Asset Management
New York
– -$76K -35,596 Closed
KPF
73
K2 Principal Fund
Ontario, Canada
– -$62K -29,060 Closed
US Bancorp
74
US Bancorp
Minnesota
– -$31K -14,307 Closed
SG Americas Securities
75
SG Americas Securities
New York
– -$26K -12,126 Closed
1 2
3
4

ARLZ Hedge Fund Activity: Q2 2017 in Review

72 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Aralez Pharmaceuticals Inc. (ARLZ) for Q2 2017, worth a combined $21.5M — down 57% from $50.2M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of ARLZ and 11 opened new positions — a net loss of 5 holders — while 25 trimmed existing stakes and 17 added.

The largest buyer was GSA Capital Partners, adding an estimated $367K. The largest seller was Elk Creek Partners, exiting entirely with an estimated $5.33M sold.

  • 72 institutional investors held Aralez Pharmaceuticals Inc. (ARLZ) as of Q2 2017, down from 78 in Q1 2017.
  • Funds reported $21.5M of Aralez Pharmaceuticals Inc. stock for Q2 2017, down 57% quarter-over-quarter.
  • 11 funds opened new Aralez Pharmaceuticals Inc. positions in Q2 2017 and 16 closed out, a net change of -5 holders.
  • The largest Aralez Pharmaceuticals Inc. buyer in Q2 2017 was GSA Capital Partners, an estimated $367K added.
  • The largest Aralez Pharmaceuticals Inc. seller in Q2 2017 was Elk Creek Partners, an estimated $5.33M sold.

Based on aggregated 13F filings for Q2 2017.